Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPM1 | P06748 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958660 | 0.85 | RAB9A (0.58) | ALDH1A1LMNAKDM4EMAPTNPC1 | |
| SCHEMBL24007903 | 0.82 | MAPT (0.49) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20982482 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4EMAPTNPC1 | |
| SCHEMBL26603188 | 0.80 | ALDH1A1 (0.49) | ALDH1A1LMNAKDM4EMAPTNPC1 | |
| SCHEMBL1104857 | 0.80 | KDM4E (0.58) | ALDH1A1LMNAKDM4EMAPTNPC1 | |
| SCHEMBL31473995 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30621940 | 0.79 | MAPT (0.47) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL14247671 | 0.79 | MAPT (0.47) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL17674019 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31031662 | 0.79 | MAPT (0.47) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774805-B1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER LAB (FR) | 2024-01-10 | — | — | EP | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111936499-B | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2023-09-19 | — | — | CN | disclosed |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | SERVIER PHARMACEUTICALS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-3902804-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Les Laboratoires Servier SAS (FR) | 2021-11-03 | — | — | EP | disclosed |
| CN-113474347-A | AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2021-10-01 | — | — | CN | disclosed |
| US-20210115045-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC | 2021-04-22 | — | — | US | disclosed |
| EP-2324017-A2 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2297163-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010010157-A2 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010157-A2 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115045-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | ALDH1A1 1700/4885LMNA 2206/4885KDM4E 1670/4885 |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | ALDH1A1 164/4885LMNA 3535/4885KDM4E 1055/4885 |
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | ALDH1A1 718/4885LMNA 3133/4885KDM4E 693/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | ALDH1A1 4726/4885LMNA 3635/4885KDM4E 4351/4885 |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | MAT2A, MAT2B, MAT1A | ALDH1A1 1700/4885LMNA 2206/4885KDM4E 1670/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 98/4885LMNA 2828/4885KDM4E 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.